Breakthrough provider of affordable online life insurance for diabetes and other chronic conditions. Based on proprietary analysis of a substantial NHS data set not available to industry incumbents.

The market is estimated to be worth £4bn+ due to sobering statistic that 1 in 2 people globally will develop a chronic health condition, restricting and often preventing them obtaining life insurance. This represents a massive and underserved addressable market of people with no insurance who want to obtain it.

Diabetes is the first of these to be addressed by Blueberry Life, with a roadmap to apply similar techniques to these otherwise uninsurable risks.

The Company is FCA regulated and has already achieved encouraging commercial traction, with £314k of sales to date from 386 policies sold (£25m+ in policy cover issued by top (re)insurer partners Gen Re and Shepherds Friendly) since launching in June 2023, c2x year-on-year growth for 2025, several distribution partners already engaged, and a sales pipeline of £4.3m.

Blueberry Life has raised c£3m in equity funding to date, which has been used to build the product, bring it to market and secure validation from professional insurers, underwriters and customers.

The Company is currently raising up to £2m (EIS qualifying), of which £1.36m has already been invested by VCs (including two specialist InsurTech funds) at a £8m pre-money valuation.

Your VC has secured an allocation of up to £300k of the round for its investors. Management is in negotiation with other VCs and potential investors to cover the remaining £300k.

Existing VC shareholder has indicated their intention to invest a further £500k after Blueberry Life has achieved the key milestone of launching on PCW platforms (expected to occur in Q4 2026).